Safety and Efficacy of Liraglutide in Parkinson's Disease

NCT02953665 on ClinicalTrials.gov · last registry update 2024-03-07

Finished 3 August 2022, after enrolling 63 people. liraglutide is approved in the US, but not for neurodegenerative — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Cedars-Sinai Medical Center
Sponsor type: Other
Enrollment: 63
Started: 2017-04-03
Primary completion: 2022-08-03 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Unified Parkinson's Disease Rating Scale (UPDRS Part III Motor Examination) During "OFF" Time From Baseline to the End of Double-Blind Maintenance Period

Conditions studied

Parkinson Disease

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.